Disease · MONDO_0016167

optic pathway glioma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. optic pathway glioma. Diseases, record MONDO_0016167. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0016167

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: optic pathway glioma; Open Targets
Open Targets ID: MONDO_0016167; Open Targets
Other names: glioma of optic tract, glioma of the optic tract, glioma of the visual pathway, glioma of visual pathway, optic tract glioma, visual pathway glioma; Open Targets
NCI Thesaurus: C8567; NCI Thesaurus
Orphanet: ORPHA:2086; Orphanet
Highest stage of its drugs: Phase 3, for 3 of its 12 drugs, from ClinicalTrials.gov; Open Targets

Drugs12

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
SELUMETINIB	CHEMBL1614701	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
VINBLASTINE	CHEMBL159	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
TEMOZOLOMIDE	CHEMBL810	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ENDOSTATIN	CHEMBL4297747		Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
ENDOSTATIN, N-TERMINAL-MGGSHHHHH	CHEMBL4297946		Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
INTERFERON ALFA-2B	CHEMBL1201558	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
LENALIDOMIDE	CHEMBL848	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
NERVE GROWTH FACTOR	CHEMBL4297796		Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
VINCRISTINE	CHEMBL90555	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 12

See all 12 drugs

Targets25

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
TUBA1A	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/81027	Drugs and targets
TUBB2A	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7280	Drugs and targets
TUBB2B	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/347733	Drugs and targets

1 to 10 of 25

See all 25 targets

Trials10

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01553149	Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma	Phase 2	75	2021-11-30	Neurofibromatosis Type 1, Recurrent Childhood Pilocytic Astrocytoma, Recurrent Childhood Visual Pathway Glioma	LENALIDOMIDE	Its record names the disease	ClinicalTrials.gov
NCT02343224	Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas	Phase 2	9	2022-01-24	Juvenile Pilocytic Astrocytomas, Optic Pathway Gliomas	INTERFERON ALFA-2B	Its record names the disease	ClinicalTrials.gov
NCT04576117	A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma	Phase 3	300		Recurrent Low Grade Astrocytoma, Recurrent WHO Grade 2 Glioma, Refractory Low Grade Astrocytoma, Refractory Low Grade Glioma, Refractory WHO Grade 1 Glioma	SELUMETINIB, VINBLASTINE	Its record names the disease	ClinicalTrials.gov
NCT04166409	A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma	Phase 3	170		Low Grade Astrocytoma, Low Grade Glioma, Metastatic Low Grade Astrocytoma, Metastatic Low Grade Glioma, WHO Grade 1 Glioma, WHO Grade 2 Glioma	SELUMETINIB	Open Targets' reading of its record	ClinicalTrials.gov
NCT05278715	Modified CV Regimen in Optic Pathway Glioma	Phase 2	75		Optic Glioma, Pediatric Brain Tumor, Optic Nerve Glioma	CARBOPLATIN, VINCRISTINE	Its record names the disease	ClinicalTrials.gov
NCT00575796	Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)	Phase 2	50		Glioma	VINBLASTINE	Its record names the disease	ClinicalTrials.gov
NCT05733572	Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)	Phase 2	36		Optic Pathway Glioma	NERVE GROWTH FACTOR	Its record names the disease	ClinicalTrials.gov
NCT02115074	Safety of Fluvastatin-Celebrex Association in Low-grade and High Grade Optico-chiasmatic Gliomas	Phase 1	20		Glioma	CELECOXIB, FLUVASTATIN	Its record names the disease	ClinicalTrials.gov
NCT03326388	Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours	Phase 1/2	14		Neurofibromatosis Type 1, Plexiform Neurofibroma, Optic Nerve Glioma	SELUMETINIB	Its record names the disease	ClinicalTrials.gov
NCT01260103	Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma	Phase 3	0		Optic Nerve Glioma	TEMOZOLOMIDE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials5

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Arm I (Low-dose Lenalidomide) vs Arm II (High-dose Lenalidomide): Number of Patients With Toxic Events After 2 Dose Reductions	2 of 37	16 of 37	74	NCT01553149	Trial comparisons
Arm I (Low-dose Lenalidomide) vs Arm II (High-dose Lenalidomide): deaths from any cause	4 of 37	4 of 37	74	NCT01553149	Trial comparisons
Arm I (Low-dose Lenalidomide) vs Arm II (High-dose Lenalidomide): Number of Patients Who Demonstrate Early Progression	6 of 37	4 of 37	74	NCT01553149	Trial comparisons
Arm I (Low-dose Lenalidomide) vs Arm II (High-dose Lenalidomide): Number of Patients Who Demonstrate Complete or Partial Response	4 of 37	4 of 37	74	NCT01553149	Trial comparisons
Arm I (Low-dose Lenalidomide) vs Arm II (High-dose Lenalidomide): serious adverse events	6 of 37	16 of 37	74	NCT01553149	Trial comparisons

Papers from its trials8

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
26767384	RESULT	1	PubMed
25408174	RESULT	1	PubMed
21444653	RESULT	1	PubMed
21343523	RESULT	1	PubMed
37126770	DERIVED	1	PubMed
33395032	DERIVED	1	PubMed
32597469	DERIVED	1	PubMed
27573663	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0016167

GET https://conductscience.org/api/diseases/v1/MONDO_0016167/targets?page=2

API reference For AI assistants